SEARCH

SEARCH BY CITATION

References

  • 1
    Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 2006; 50: 9359.
  • 2
    Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 2001; 86: 72431.
  • 3
    Vermeulen A. Andropause. Maturitas 2000; 34: 515.
  • 4
    Leifke E, Gorenoi V, Wichers C et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin. Endocrinol. 2000; 53: 68995.
  • 5
    Statin P, Lumme S, Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer 2004; 108: 41824.
  • 6
    Anderson DC, Thorner MO, Fisher RA, Woodham JP, Goble HL, Besser GM. Effects of hormonal treatment on plasma unbound androgen levels in hirsute women. Acta Endocrinol. 1975; 199 (Suppl): 224.
  • 7
    Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 1999; 84: 366672.
  • 8
    Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002; 51: 5549.
  • 9
    Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 225760.
  • 10
    Miller KK, Rosner W, Lee H et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J. Clin. Endocrinol. Metab. 2004; 89: 52533.
  • 11
    Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J. Urol. 2000; 163: 8247.
  • 12
    Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 528.
  • 13
    Yano M, Imamoto T, Suzuki H et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur. Urol. 2007; 51: 2935.
  • 14
    Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am. J. Clin. Oncol. 1997; 20: 6058.
  • 15
    Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 2003; 169: 16705.
  • 16
    Imamoto T, Suzuki H, Fukasawa S et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur. Urol. 2005; 47: 30812.
  • 17
    Isom-Batz G, Bianco FJ Jr, Kattan MW et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J. Urol. 2005; 173: 19357.
  • 18
    Imamoto T, Suzuki H, Akakura K et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr. J. 2001; 48: 5738.
  • 19
    Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 1991; 265: 61821.
  • 20
    Platz EA, Leitzmann MF, Rifai N et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 12629.
  • 21
    Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 2002; 53: 17982.
  • 22
    Teloken C, Da Ros CT, Caraver F et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J. Urol. 2005; 174: 217880.
  • 23
    Partin AW, Pound CR, Clemens JQ et al. Serum PSA after anatomic radical retropubic prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. North Am. 1993; 20: 71325.
  • 24
    Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001; 28: 55565.
  • 25
    Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand. J. Urol. Nephrol. Suppl. 1994; 157: 417.
  • 26
    Miller LR, Partin AW, Chan DW et al. Influence of radical prostatectomy on serum hormone levels. J. Urol. 1998; 160: 44953.
  • 27
    Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999; 59: 41614.
  • 28
    Lukkarinen O, Hammond GL, Kontturi M et al. Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand. J. Urol. Nephrol. 1980; 14: 2257.
  • 29
    Madersbacher S, Schatzl G, Bieglmayer C et al. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 2002; 60: 86974.
  • 30
    Phadke MA, Vanage GR, Sheth AR. Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. Prostate 1987; 10: 11522.
  • 31
    Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res. 1993; 53: 48559.
  • 32
    Sheth AR, Garde SV, Mehta MK, Shah MG. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J. Exp. Biol. 1992; 30: 15761.
  • 33
    Ghosh PK, Ghosh D, Ghosh P, Chaudhuri A. Effects of prostatectomy on testicular androgenesis and serum levels of gonadotropins in mature albino rats. Prostate 1995; 26: 1922.
  • 34
    Risbridger GP, Shibata A, Ferguson KL et al. Elevated expression of inhibin alpha in prostate cancer. J. Urol. 2004; 171: 1926.
  • 35
    Yamamoto S, Yonese J, Kawakami S et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur. Urol. 2007; 52: 696701.
  • 36
    Bosland MC. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. 2000; 27: 6773.
  • 37
    Hsing AW. Hormones and prostate cancer: what's next? Epidemiol. Rev. 2001; 23: 4258.
  • 38
    Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003; 349: 21524.
  • 39
    Morgentaler A, Bruning CO III, DeWolf WC. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 1996; 276: 19046.
  • 40
    Scardino PT. The prevention of prostate cancer – the dilemma continues. N. Engl. J. Med. 2003; 349: 2979.
  • 41
    Schatzl G, Madersbacher S, Haitel A et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J. Urol. 2003; 169: 131215.
  • 42
    Raivio T, Santti H, Schatzl G et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003; 55: 1948.
  • 43
    Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J. Urol. 2006; 176: 138791.
  • 44
    Carver BS, Kattan MW, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int. 2005; 95: 50912.
  • 45
    Rubin MA, Allory Y, Molinie V, Lery X, Faucon H, Vacherot F. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005; 66: 9304.
  • 46
    Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J. Clin. Oncol. 2005; 23: 754654.
  • 47
    Morimoto I, Edmiston A, Hawks D, Horton R. Studies on the origin of androstanediol and androstanediol glucuronide in young and elderly men. J. Clin. Endocrinol. Metab. 1981; 52: 7728.
  • 48
    Thigpen AE, Davis DL, Milatovich A et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. Clin. Invest. 1992; 90: 799809.
  • 49
    Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 1998; 63: 20813.
  • 50
    Stanczyk FZ, Skinner EC, Mertes S, Spahn MF, Lobo RA, Ross RK. Alterations in circulating levels of androgens and PSA during treatment with finasteride in men at high risk for prostate cancer. In: LiJJ, LiSA, GustafssonJ-A, NandiS, SekelyLL (eds). Hormone Carcinogenesis II, Proceedings of the Second International Symposium. Springer-Verlag New York, Inc., New York, 1996; 4047.
  • 51
    Irani J, Ravery V, Pariente JL et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol. 2002; 168: 19858.
  • 52
    Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 33203.
  • 53
    Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22: 31816.
  • 54
    Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 2001; 195: 13846.
  • 55
    Shimbo M, Suzuki H, Kamiya N et al. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur. Urol. 2005; 47: 55763.
  • 56
    Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941; 43: 20912.
  • 57
    Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer 1999; 80: 9304.
  • 58
    Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 2000; 3: 15772.
  • 59
    Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 21335.
  • 60
    Heikkila R, Aho K, Heliovaara M et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999; 86: 31215.
  • 61
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst. 1996; 88: 111826.
  • 62
    Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1993; 2: 2732.
  • 63
    Guess HA, Friedman GD, Sadler MC et al. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 214.
  • 64
    Vatten LJ, Ursin G, Ross RK et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 9679.
  • 65
    Dorgan JF, Albanes D, Virtamo J et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 106974.
  • 66
    Fears TR, Ziegler RG, Donaldson JL et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol. Biomarkers Prev. 2000; 9: 40312.
  • 67
    Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 6215.
  • 68
    Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3: 56574.
  • 69
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 2003; 348: 162538.
  • 70
    Giovannucci E, Rimm EB, Liu Y et al. Body mass index and risk of prostate cancer in U.S. Health professionals. J. Natl. Cancer Inst. 2003; 95: 12404.
  • 71
    Kato T, Suzuki H, Komiya A et al. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. Int. J. Urol. 2006; 13: 91519.
  • 72
    Ross RK, Pike MC, Coetzee GA et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998; 58: 4497504.
  • 73
    Ross RK, Bernstein L, Lobo RA et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 8879.
  • 74
    Schaeffer EM, Walsh PC. Risks of testosterone replacement. N. Engl. J. Med. 2004; 350: 20046.
  • 75
    Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 2004; 350: 48292.
  • 76
    Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. 2003; 24: 299311.
  • 77
    Barqawi AB, Crawford ED. Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int. J. Impot. Res. 2005; 17: 4623.
  • 78
    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 2006; 68: 12637.
  • 79
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4 ng per milliliter. N. Eng J. Med. 2004; 350: 223946.
  • 80
    Jorgensen T, Kanagasingam Y, Kaalhus O et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian prostatic cancer group study-2. J. Urol. 1997; 158: 16470.
  • 81
    Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 2002; 89: 71013.
  • 82
    Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone – a determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997; 49: 32734.
  • 83
    Ishihara M, Suzuki H, Akakura K et al. Baseline health-related quality of life in the management of prostate cancer. Int. J. Urol. 2006; 13: 9205.
  • 84
    Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int. J. Urol. 2007; 14: 41621.
  • 85
    Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5a-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 1993; 77: 37581.
  • 86
    Slater S, Oliver RTD. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 4319.
  • 87
    Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995; 27: 2531.
  • 88
    Chen C, Weiss NS, Stanczyk FZ et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 141016.
  • 89
    Liverman CT, Blazer DG (eds). Testosterone and Aging: Clinical Research Directions. National Academies Press, Washington, DC, 2004.
  • 90
    Prezioso D, Denis LJ, Klocker H et al. Estrogens and aspects of prostate disease. Int. J. Urol. 2007; 14: 116.
  • 91
    Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 235161.
  • 92
    Bhasin S, Woodhouse L, Casaburi R et al. Testosterone dose–response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 2001; 281: 117281.
  • 93
    Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 2000; 85: 26707.
  • 94
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 2001; 56: 26672.
  • 95
    Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 1999; 84: 196672.
  • 96
    Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 1997; 82: 16617.
  • 97
    Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 1999; 84: 346978.
  • 98
    Wang C, Swerdloff RS, Iranmanesh A et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000; 85: 283953.
  • 99
    Singh AB, Hsia S, Alaupovic P et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J. Clin. Endocrinol. Metab. 2002; 87: 13643.
  • 100
    Cooper CS, Perry PJ, Sparks AET, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J. Urol. 1998; 159: 4413.
  • 101
    Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J. Urol. 2003; 170: 234851.
  • 102
    Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int. J. Impot. Res. 2006; 18: 2015.
  • 103
    Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 53641.
  • 104
    Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur. Urol. 2007; 52: 6235.
  • 105
    Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur. Urol. 2004; 46: 28595.
  • 106
    Matias JRDCI, Malloy V, Orentreich N. Inhibition of prostate cancer in rats by the administration of dehydroepiandrosterone. Ann. N. Y. Acad. Sci. 1987; 453: 31628.
  • 107
    Voermans C, Condon MS, Bosland MC. Growth inhibition by dehydroepiandrosterone of human prostate cancer cell lines and primary epithelial cultures of rat prostate carcinomas (meeting abstract). Proc. Annu. Meet Am. Assoc Cancer Res. 1996; 37: A1933.
  • 108
    Rao KV, Johnson WD, Bosland MC et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 1999; 59: 30849.